We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Oncology Biomarker Database Includes Cancer Companion Diagnostic Pathway

By LabMedica International staff writers
Posted on 29 Dec 2011
A comprehensive cancer biomarker database has been launched that can help in finding new diagnostic, prognostic, and companion diagnostic biomarkers.

The database includes cancer companion-diagnostics biomarker pathway maps. More...
It contains more than 8,500 discovery phase, preclinical, or clinical cancer biomarkers that were identified or validated using patient derived samples.

Sciclips (Madison, MI, USA) launched the database, which covers a wide variety of biomarkers such as blood cancer biomarkers (peripheral blood, plasma, serum etc), tumor biomarkers, urinary cancer biomarkers, fecal cancer biomarkers, saliva cancer biomarkers, breath cancer biomarkers, etc.

More than 100 types of cancer are included in the cancer biomarker database. For each cancer type, the biomarkers are classified into diagnostic biomarkers; for the diagnostics application, disease predictive/risk assessment biomarkers; for predicting the risk or genetic susceptibility in developing cancer; drug efficacy/response biomarkers; biomarkers for studying the efficacy of anticancer drug treatments, including predictive biomarkers and prognostic biomarkers; and for determining the clinical outcome in cancer patients.

The types of cancer biomarkers include protein biomarkers, miRNA biomarkers, single-nucleotide polymorphism (SNP) biomarkers, gene expression biomarkers, epigenetic biomarkers, and metabolomic biomarkers.

With the growing trend of personalized healthcare concept and advance in biomarker research, there is a need for development of innovative personalized cancer drugs with companion biomarker assays to identify the most appropriate cancer patient, tumor type, and disease state.

Patient/sample details, experimental results, observations, biological and molecular functional analysis, biological process analysis, protein-protein interaction networks of each biomarker are listed in the database.

The pathway maps will help to identify new anticancer drug predictive and response biomarkers, for the discovery of new drug targets with improved efficacy or targeted therapy to overcome side effects, patient stratification, developing personalized strategies for monitoring cancer progression, treatment, diagnosis, and prognosis.

Related Links:

Sciclips




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.